A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
Phase 2 Completed
108 enrolled 13 charts
Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC
Phase 1 Completed
16 enrolled
AASUR in High Risk Prostate Cancer
Phase 2 Completed
64 enrolled 7 charts
PC-ARN
Phase 2 Completed
93 enrolled
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
Phase 1/2 Completed
127 enrolled 16 charts
PILLAR
Phase 2 Completed
26 enrolled 11 charts
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Phase 3 Completed
504 enrolled
PANTHER
Phase 2 Completed
93 enrolled 17 charts
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Phase 1 Completed
48 enrolled
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
Phase 2 Completed
28 enrolled 10 charts
Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
Phase 2 Completed
118 enrolled 23 charts
Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate
Phase 1 Completed
6 enrolled
A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
Phase 2 Completed
39 enrolled 15 charts
A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study
Phase 1 Completed
45 enrolled
ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
Phase 1 Completed
9 enrolled
Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer
Phase 2 Completed
64 enrolled
Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer
Phase 2 Completed
86 enrolled 9 charts
Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer
Phase 2 Completed
54 enrolled 13 charts
A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer
Phase 1 Completed
33 enrolled
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy
Phase 2 Completed
22 enrolled 11 charts
Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels
Phase 2 Completed
128 enrolled
A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)
Phase 1 Completed
34 enrolled
Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer
Phase 2 Completed
30 enrolled
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Phase 2 Completed
90 enrolled 23 charts
TAPS01
Phase 2 Completed
11 enrolled